Hormone replacement therapy, also known as hormone therapy, is a means of
replacing hormones that are no longer being produced by the body. This type of
therapy is usually initiated at menopause or may be started while a woman is in
the perimenopausal phase, nearing menopause. Hormone replacement therapy
replenishes the hormones required by the human body to function by using
bio-identical hormones. The therapy contains estrogen and progesterone, and in
some cases testosterone, to reduce symptoms of menopause. This replacement
therapy may also protect against osteoporosis, reduce the risk of coronary
heart disease, and may prevent or delay the onset of Alzheimer’s disease.
Replacement therapy can also increase the chance of developing more serious
health complications such as blood clots, breast cancer, uterine cancer, and
bowel cancer.
Analysts forecast the Global Hormone
Replacement Therapy market will grow at
a CAGR of 2.51 percent over the period 2013-2018.
The Report recognizes the following companies as the key players in the
Global Hormone Replacement Therapy Market: Actavis plc, Bayer AG , Merck &
Co. Inc., Novartis AG , Novo Nordisk A/S , Abbott Laboratories Ltd., Amgen Inc.,
ANI Pharmaceuticals Inc., Hisamitsu Pharmaceutical Co. Inc., MylanLaboratories
Inc., Orion Corp., QuatRx Pharmaceuticals Co., Teva Pharmaceutical Industries
Ltd., TherapeuticsMD Inc.
The Global Hormone Replacement Therapy market is experiencing increased
interest in non-hormonal therapies. This trend shift toward non-hormonal
therapies for menopausal symptoms and osteoporosis has been apparent since the
Women’s Health Initiative Study in 2002. In 2013, the US FDA approved the first
non-hormonal treatment, Brisdelle (paroxetine), to treat vasomotor symptoms
associated with menopause.
Covered in this
Report
The Global Hormone Replacement Therapy market can be divided into three
segments: Estrogen Replacement Therapy, Growth Hormone Replacement Therapy, and
Thyroid Hormone Replacement Therapy. This report covers the present scenario
and the growth prospects of the Global Hormone Replacement Therapy market for
the period 2014-2018. To calculate the market size, the report considers the
revenue generated from the sales of the various hormone replacement therapies
that are available in the market.
Global Hormone Replacement Therapy Market 2014-2018, has been prepared
based on an in-depth market analysis with inputs from industry experts. The
report covers the Americas, EMEA, and APAC regions; it also covers the Global
Hormone Replacement Therapy market landscape and its growth prospects in the
coming years. The report also includes a discussion of the key vendors
operating in this market.
According to the report, one of the main drivers in this market is the
significant unmet need for HRT. The current treatment options are incapable of
meeting the market requirements because of their lower safety profiles, leaving
a large amount of unmet need in this market. The need for new treatment options
with better safety results to address the current unmet need is huge.
Further, the report states that the Global HRT market faces some serious
challenges. One of the main challenges is the high cost of HRT, which hinders
its acceptance by patients. Many patients do not have the required budget to invest
in high-cost treatment options. Adverse side effects of HRT are another major
factor hampering the growth of the Global HRT market.
